News Releases

Select Access™ to Co-Promote Allergan’s Zymar® to Primary Care Physicians

Five year agreement leverages Select Access capacity in performance-based model

Saddle River, NJ— (July 19, 2005) PDI, Inc. (NASDAQ: PDII) a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries, today announced that its Select Access™ unit has been selected by Allergan, Inc. (NYSE: AGN) to co-promote Zymar® (gatifloxacin ophthalmic solution 0.3%), the first FDA-approved fourth generation topical fluoroquinolone indicated for the treatment of bacterial conjunctivitis, to primary care practitioners. Zymar® represents a recent advance in countering emerging antimicrobial resistance and is currently the No. 1 prescribed fluoroquinolone among ophthalmologists.

Select Access™ has a unique selling model where multiple, non-competitive clients can access a fully operational sales force. Since the sales team, and its cost, are leveraged across multiple clients, Select Access™ is effective for over-the-counter, established and seasonal products. In this agreement with Allergan, Select Access™ will receive payment on a performance basis, instead of its customary fee-for-service schedule.

“This is a win-win agreement with Allergan,” said Christopher Tama, PDI’s Executive Vice President and General Manager of Diversified Teams. “Allergan is getting sales support for a promotionally responsive product and pays on a performance basis. Select Access™ leverages part of its capacity with an opportunity to greatly improve its profitability. We are not changing our fee based model in Select Access™, but because Allergan is a longstanding PDI client with an excellent product, we believe this is a great opportunity to expand the Select Access™ business model.”

About Select Access

Select Access™, a targeted sales solution for a diverse group of pharmaceutical products, leverages an existing infrastructure to maximize brand profitability. Rapid deployment and national coverage by 400 experienced sales representatives in high prescribing territories increases speed to impact. Select Access™ is the only alternative sales force model that gives clients complete target audience control and flexibility and where the majority of sales calls are single detail.

Select Access’™ unmatched value is perfectly aligned to increase incremental revenue for established brands, OTC brands, and for specialty brands that could gain an additional revenue stream from a primary care presence.

For more information, visit the website at www.select-access.com.

About PDI

PDI, Inc. (NASDAQ:PDII) is a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries. PDI’s comprehensive set of next-generation solutions is designed to increase its clients’ strategic flexibility and enhance their efficiency and profitability. Headquartered in Saddle River, NJ, PDI also has offices in Pennsylvania and Illinois.

PDI’s sales and marketing services include dedicated, shared, clinical and combination sales teams; marketing research and consulting; medical education and communications; talent recruitment; and integrated commercial solutions from pre-launch through patent-expiration. The company’s experience extends across multiple therapeutic categories and includes office and hospital-based initiatives.

PDI’s commitment is to deliver innovative solutions, excellent execution and superior results to its clients. Through strategic partnership and client-driven innovation, PDI maintains some of the longest sales and marketing relationships in the industry. Recognized as an industry pioneer, PDI continues to innovate today as a thought-starter for the outsourcing of sales and marketing services.

For more information, visit the Company’s website at www.pdi-inc.com.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients’ lives.

For more information, visit the Company’s website at www.allergan.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, changes in our operating expenses, adverse patent rulings, FDA, legal or accounting developments, competitive pressures, failure to meet performance benchmarks in significant contracts, changes in customer and market requirements and standards, the impact of any stock repurchase programs, and the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2004, and PDI’s periodic reports on Form 8-K filed with the Securities and Exchange Commission since January 1, 2005. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Copyright © Select Access, a division of PDI, Inc. • Information Privacy Policy

About Select Access | Markets Served | Press & Media | Target Coverage Analysis | Contact Us | PDI, Inc.